Infection prevention products manufacturer Tristel (TSTL) has announced results for its half-year ended 31st December 2022 emphasising “achieving 16% revenue growth and a 16-fold increase in EBITDA”. So what of the shares currently up to 330p, but still down from when I previously concluded bearishly a year ago?
Previously writing on 'infection prevention products' company Tristel (TSTL), in October with the shares down to around 500p I concluded that still the valuation suggested entry into the US at a vast value indeed is needed and to avoid / sell. With the shares having last closed at 417.5p, what of today-announced half year results?...
Previously writing on 'infection prevention products' company Tristel (TSTL), in July with the shares at 620p I reviewed why they were down in response to ‘confident for strong growth’ update. Today full-year results, and the shares are further down.
'Infection prevention products' company Tristel (TSTL) has announced positive performance against expectations and confidence “for strong growth in the years ahead”. Why then are the shares, at 620p, currently more than 6% lower?...
A “trading update” announcement from infection prevention and contamination control products company Tristel (TSTL) yesterday morning saw the shares down approaching 16% at 563p as I then wrote. What then of CEO Paul Swinney having since purchased shares at 572.75p each?
A trading update from infection prevention and contamination control products company Tristel (TSTL) includes “surface disinfectant product sales have continued to gain market share and UK sales for this product range to end of third quarter were £2.3m, 47% higher than in the same period last year” and “sales of our 13 overseas subsidiaries and to our international distributor network have increased by 7% over the comparable period last year”. So why are the shares, at 563p, currently approaching 16% down?...
